|
Mar 16, 2020
|
Catalyst Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update
-Firdapse ® Q4 Net Revenues of $30 Million , FY 19 Net Revenues of $102 Million -GAAP Net Income of $32 Million for Fiscal Year 2019 -Catalyst Reiterates Net Revenue Guidance in the Range of $135 Million to $155 Million for FY 2020 -Firdapse Supply Chain in Solid Position-Significant Safety Stock
|
|
|
Mar 10, 2020
|
Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 17th, 2020
CORAL GABLES, Fla. , March 10, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological
|
|
|
Feb 27, 2020
|
Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2020
CORAL GABLES, Fla. , Feb. 27, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological
|
|
|
Feb 26, 2020
|
Catalyst Pharmaceuticals to Present at the Cowen 40th Annual Health Care Conference
CORAL GABLES, Fla. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological
|
|
|
Feb 06, 2020
|
Catalyst Pharmaceuticals to Present at the 22nd Annual BIO CEO & Investor Conference
CORAL GABLES, Fla. , Feb. 06, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological
|
|
|
Feb 04, 2020
|
Catalyst Pharmaceuticals Appoints David Ailinger as Vice President, Business Development
CORAL GABLES, Fla. , Feb. 04, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological
|
|
|
Jan 06, 2020
|
Catalyst Pharmaceuticals Pre-Announces Estimated Firdapse® Revenues and Provides Updates on Advancement of Clinical Development Programs
- Firdapse 2019 Net Product Revenues Expected to be Approximately $102 Million - Anticipates Full Year 2020 Firdapse Net Product Revenues to be in the Range of $135 million to $155 million - MuSK-MG Clinical Trial Has Met Enrollment Goals and is on Schedule to Report Top-Line Results in First Half
|
|
